Condition
Hypomethylating Agents
Total Trials
2
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
P 1 (1)
Trial Status
Unknown1
Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT04999943Phase 1Recruiting
Hypomemylating Agents Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome
NCT04454580Unknown
Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy
Showing all 2 trials